Synthesis and biodistribution of a short nonionic oligonucleotide analogue in mouse with a potential to mimic peptides

Journal of Medicinal Chemistry

Volumn 41, Issue 3, 1998, Pages 276-283

  Eschgfäller, Bernd ^a,b   König, Marcel ^a   Boess, Franziska ^c   Boelsterli, Urs A ^c   Benner, Steven A ^b  

^a ETH ZURICH   (Switzerland)

^b University of Florida ^*  (United States)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

OLIGONUCLEOTIDE; RNA DERIVATIVE; SULFONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG FECES LEVEL; DRUG SYNTHESIS; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROGEN BOND; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; LUNG; MALE; MOUSE; NONHUMAN; RADIOISOTOPE DISTRIBUTION; SPLEEN;

ANIMALS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MOLECULAR MIMICRY; MOLECULAR STRUCTURE; OLIGONUCLEOTIDES; PEPTIDES; SPECTROMETRY, MASS, FAST ATOM BOMBARDMENT; TISSUE DISTRIBUTION;

EID: 0032576704     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970538o     Document Type: Article

References (32)

1. Elion, G. B. The purine path to chemotherapy. Science 1989, 244, 41-47.
2. Hitchings, G. H. Selective inhibitors of dihydrofolate reductase (Nobel Lecture). Angew. Chem., Int. Ed. Engl. 1989, 28, 879-885.
3. Uhlmann, E.; Peyman, A. Antisense oligonucleotides: A new therapeutic principle. Chem. Rev. (Washington, D.C.) 1990, 90, 543-584.
4. Wickstrom, E. In Prospects for Antisense Nucleic Acid Therapy of Cancer and Aids; Wickstrom, E., Ed.; Wiley-Liss: New York, 1991.
5. Milligan, J. F.; Matteucci, M. D.; Martin, J. C. Current concepts in antisense drug design. J. Med. Chem. 1993, 36, 1923-1937.
6. Stein, C. A.; Chen, Y.-C. Antisense oligonucleotides as therapeutic agents-Is the bullet really magical? Science 1993, 261, 1004-1012.
7. Crooke, S. T. Therapeutic applications of oligonucleotides. Annu. Rev. Pharm. Tox. 1992, 32, 327-374.
8. Richert, C.; Roughton, A. L.; Benner, S. A. Nonionic analogues of RNA with dimethylene sulfone bridges. J. Am. Chem. Soc. 1996, 118, 4518-4531.
9. Blättler, M. O.; Wenz, C.; Pingoud, A.; Benner, S. A. Distorting duplex DNA by dimethylene sulfone substitutions: A new class of inhibitor for restriction enzymes, J. Am. Chem. Soc., submitted 1997.
10. Agrawal, S.; Temsamani, J.; Tang, J. Y. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 7595-7599.
11. Chem, T.-L.; Miller, P. S.; Ts'o, P. O. P.; Colvin, O. M. Disposition and metabolism of oligodeoxynucleoside methylphosphonate following a single iv injection in mice. Drug Metab. Dispos. 1990, 18, 815-818.
12. Temsamani, J.; Tang, J. Y.; Padmapriya, A.; Kubert, M.; Agrawal, S. Pharmacokinetics, biodistribution and stability of capped oligodeoxynucleotide phosphorothioates in mice. Antisense Res. Dev. 1993, 3, 277-284.
13. Iversen, P.; Mata, J.; Tracewell, W. G.; Zon, G. Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion. Antisense Res. Dev. 1994, 4, 43-52.
14. Zhang, R.; Lu, Z.; Zhao, H.; Zhang, X.; Diasio, R. B.; Habus, I.; Jiang, Z.; Iyer, R. P.; Yu, D.; Agrawal, S. In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats. Biochem. Pharmacol. 1995, 50, 545-556.
15. Zhang, R.; Diasio, R. B.; Lu, Z.; Liu, T.; Jiang, Z.; Galbraith, W. M.; Agrawal, S. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem. Pharmacol. 1995, 49, 929-939.
16. Huang, Z.; Schneider, K. C.; Benner, S. A. Building blocks for oligonucleotide analogues with dimethylene sulfide, sulfoxide, and sulfone groups replacing phosphodiester linkages. J. Org. Chem. 1991, 56, 3869-3882.
17. Huang, Z.; Benner, S. A. Selective protection and deprotection procedures for thiol and hydroxyl groups. SynLett 1993, 83-84.
18. Buter, J.; Kellogg, R. M. Synthesis of macrocyclic and medium ring dithia compounds using cesium thiolates. J. Chem. Soc., Chem. Commun. 1980, 1980, 466-468.
19. Buter, J.; Kellogg, R. M. Synthesis of sulfur-containing macro-cycles using cesium thiolates. J. Org. Chem. 1981, 46, 4481-4485.
20. Trost, B. M.; Curran, D. P. Chemoselective oxidation of Sulfides to sulfones. Tetrahedron Lett. 1981, 22, 1287-1290.
21. Huang, Z. Dissertation No. 10429, ETH Zurich, Switzerland, 1993.
22. Mitsunobu, O. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products. Synthesis 1981, 1981, 1-28.
23. Ramirez, F.; Desai, N. B.; McKelvie, N. A new synthesis of 1,1-dibromoolefines via phosphine-dibromomethylenes. The reaction of triphenylphosphine with carbon tetrabromide. J. Am. Chem. Soc. 1962, 84, 1745-1747.
24. Verheyden, J. P. H.; Moffat, J. G. Halo sugar nucleosides. III. Reactions for the chlorination and bromination of nucleoside hydroxyl groups. J. Org. Chem. 1972, 37, 2289-2299.
25. Farese, A.; Patino, N.; Condom, R.; Dalleu, S.; Guedj, R. Liquid-phase synthesis of a peptidic nucieic-acid dimer. Tetrahedron Lett. 1996, 37, 1413-1416.
26. Pardridge, W. M.; Boado, R. J.; Kang, Y.-S. Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 5592-5596.
27. Hanahan, D. Studies on transformation of Escherichia coli with plasmids. J. Mol. Biol. 1983, 166, 557-580.
28. Nambiar, K. P.; Stackhouse, J.; Stauffer, D. M.; Kennedy, W. P.; Eldredge, J. K.; Banner, S. A. Total synthesis and cloning of a gene coding for the ribonuclease S protein. Science 1984, 223, 1299-1301.
29. Cefalu, W. T.; Pardridge, W. M. Restrictive transport of a lipid-soluble peptide Ccyclosporin) through the blood-brain barrier. J. Neurochem. 1985, 45, 1954-1956.
30. Fahr, A. Cyclosporin clinical pharmacokinetics. Clin. Pharmacokinet. 1993, 24, 472-495.
31. Caujolle, F. M. E.; Caujolle, D. H.; Gros, S. B.; Calvet, M.-M. J. Limits of toxic and teratogenic tolerance of dimethyl sulfoxide. Ann. N.Y. Acad. Sci. 1967, 141, 110-125.
32. Rubin, L. F. Toxicity of dimethyl sulfoxide, alone and in combination. Ann. N.Y. Acad. Sci. 1975, 243, 98-103.